Armata Pharmaceuticals announced clinical and regulatory progress for its AP-SA02 multi-phage product candidate, including the submission of a Phase 3 superiority study protocol and responses to FDA comments. The company completed four engineering runs at its Los Angeles manufacturing facility and plans to initiate the Phase 3 study in the second half of 2026. Additionally, Armata received a $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million. David House was promoted to Chief Financial Officer. Armata Pharmaceuticals is a biotechnology company developing bacteriophage therapeutics for antibiotic-resistant infections.
